Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Department of Oncology to collaborate with Crescendo Biologics

The Department of Oncology has signed up to collaborate with Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics.

This collaboration will accelerate the development of CB307, Crescendo’s lead programme for PSMA positive tumours, and its follow on pipeline of CD137-directed T cell enhancing programmes.


The Department’s Human Tissue Facility, led by Dr Kerry Fisher, focuses on deepening our understanding of the tumour microenvironment to develop innovative new therapies for cancer patients.


Dr Kerry Fisher, Department of Oncology, University of Oxford, commented:

“We look forward to working with Crescendo to further explore and understand the mechanisms driving the development of cancers and applying our group’s translational expertise to advance Crescendo’s novel Humabody® programmes.”

 

Full details on the Crescendo Biologics news page

Similar stories

New Study Finds Common Virus May Improve Skin Cancer Treatment Outcomes

A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.

Oxford and GSK launch £50million immuno-prevention programme to advance novel cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

Machine Learning Enhances Detection of Multiple Cancer Types from Blood

Researchers from the University of Oxford have developed TriOx, a highly sensitive blood test that detects six cancers at their earliest stages. Published today in Nature Communications, the findings highlight the test’s potential to transform early cancer detection and improve patient outcomes.

MSc Medical Physics with Radiobiology receives IPEM accreditation

The Department of Oncology at the University of Oxford is delighted to announce that our new MSc Medical Physics with Radiobiology programme has received Masters Level Accreditation from the Institute of Physics and Engineering Medicine (IPEM).

Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer

The Oncology Department at the University of Oxford is excited to announce the forthcoming publication in the Proceedings of the National Academy of Sciences (PNAS) of the research paper “Goblet Cell Differentiation Subgroups in Colorectal Cancer.” This groundbreaking study sheds light on the role of goblet cell differentiation in colorectal cancer (CRC) and its impact on cancer progression and prognosis.

Ground-breaking Study reveals previously unknown genetic causes of Colorectal Cancer

A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).